Please ensure Javascript is enabled for purposes of website accessibility

Neuralstem Phase I trial starts in San Diego

Neuralstem Inc., of Germantown, a biotechnology company, announced that the first patient was treated last week in the Phase I trial testing its NSI-566 human neural stem cells for chronic spinal cord injury. The trial occurred at the UC San Diego School of Medicine, and the patient has been discharged from the hospital. The Phase I trial will treat four patients who have thoracic spinal cord injuries with stem cell transplants directly into the region of the injury, between one and two years post-injury. All of the patients have complete paralysis with no motor or sensory function at and below the injury.